R3: An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL)

Phase 3

Completed

• Conditions: relapsed acute lymphoblastic leukaemia in children; Cancer - Children's - Leukaemia & Lymphoma

• Registration Number: ACTRN12608000495325
• Lead Sponsor: niversity Hospitals of Leicester National Health Service (NHS) Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-09-30
• Study Completion: 2016-12-31
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 354

Inclusion Criteria

Inclusion Criteria:
1. All patients aged 1-18 years who have been previously diagnosed to have acute lymphoblastic leukaemia and have either relapsed after treatment or have primary refractory disease
2. Only those patients in whom this is the first relapse are eligible
3. Written, informed consent according to national guidelines
4. Appropriate ethical committee approval.

Exclusion Criteria

Exclusion Criteria:
1. Those who have first relapse but have already received chemotherapy or radiotherapy for the relapse, prior to starting R3
2. Patients who have had a prior bone marrow transplant
3. Those with mature B-cell A

Study & Design

• Study Type: Interventional
• Study Design: Not specified